Investigational drug · Phase 2
DB-1305
Also called: BNT325
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "DB-1305"
First trial start
2022
Jul 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DB-1305", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DB-1305" as an intervention, largest first.
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid TumorsActive, not recruiting
DualityBio Inc.Industry
NCT05438329 · 1,123 participants (planned) · Start Jul 19, 2022 · Primary completion Aug 13, 2027
Drug: DB-1305/BNT325; BNT327 · For: Advanced Solid Tumor
Sites: Bullhead City, Arizona; Cerritos, California; La Jolla, California · 93 sites in all
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
DualityBio Inc.Industry
NCT06953089 · 750 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 30, 2030
Drug: DB-1311/BNT324; BNT327 and 1 more · For: Solid Tumors
Sites: Los Angeles, California; Wheat Ridge, Colorado; Florida City, Florida · 37 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer.
Patel SP, Gadgeel S, Mino-Kenudson M, et al. · Cancer Treat Rev 2026
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.